In Brief: FDA's Ron Johnson
This article was originally published in The Gray Sheet
Executive Summary
FDA's Ron Johnson: Director of FDA's Pacific Region office joins Quintiles/BRI consulting firm, leaving FDA after 29 years with the agency. Johnson will work at the firm's San Francisco office as executive director for West Coast operations, quality systems. Johnson, whose recent projects have included work on an FDA third-party inspection proposal, became director of FDA's Pacific Region in 1994 after a three-year stint as director of the Office of Compliance in the agency's Center for Devices and Radiological Health ("The Gray Sheet" March 21, 1994, I&W-1). The Pacific Region director slot is being filled on a rotating weekly basis by FDA district officials...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.